Lipoprotein(a) [Lp(a)]: The Genetically Determined Cardiovascular Risk Factor You've Probably Never Been Tested For

Standard lipid panels measure four things: total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. For most people, those four numbers represent the sum total of their cardiovascular risk assessment. What is almost never measured — and yet has been described by the American Heart Association as an independent and causal risk factor for atherosclerotic cardiovascular disease — is Lipoprotein(a), or Lp(a).

Elevated Lp(a) is estimated to affect approximately 1.5 billion people globally. It operates independently of LDL cholesterol, meaning it can elevate cardiovascular risk even when LDL levels are within the recommended range. Unlike most modifiable cardiovascular risk factors, Lp(a) is approximately 70–90% genetically determined — lifestyle interventions have minimal impact on it. And despite all of this, it is absent from routine clinical testing in the vast majority of health systems.

This article examines the biology of Lp(a), its pathogenic mechanisms, what a result means in practice, the considerable analytical challenges involved in measuring it accurately, and what an evolving therapeutic landscape looks like for one of cardiology's most talked-about emerging targets.

1. Structure and Biology of Lp(a)

Lp(a) is a lipoprotein particle structurally similar to low-density lipoprotein (LDL). It consists of an LDL-like core — containing apolipoprotein B-100 (ApoB-100) and a lipid component that is approximately 30–45% cholesterol by mass — to which an additional glycoprotein called apolipoprotein(a) [apo(a)] is covalently attached via a single disulfide bond.

The apo(a) moiety is what makes Lp(a) functionally distinct from LDL. Apo(a) has a high degree of structural homology with plasminogen, a key enzyme in the fibrinolytic (clot-dissolving) cascade. This structural similarity allows Lp(a) to compete with plasminogen for binding sites, thereby interfering with the body's natural ability to dissolve blood clots — a pro-thrombotic effect that does not exist with standard LDL particles.

A defining structural feature of apo(a) is the presence of a variable number of repeated structural motifs called kringle IV type 2 (KIV-2) repeats. The number of these repeats differs between individuals — and between an individual's two inherited copies — giving rise to more than 40 different apo(a) isoforms. Isoform size is inversely related to plasma Lp(a) concentration: smaller isoforms (fewer KIV-2 repeats) are generally associated with higher Lp(a) levels. This structural heterogeneity also makes Lp(a) one of the most analytically challenging biomarkers to measure accurately, a theme returned to in detail below.

2. Genetics and Epidemiology: A Biomarker Largely Set at Birth

Plasma Lp(a) concentrations are approximately 70–90% determined by the LPA gene, which encodes apo(a). This degree of heritability is extraordinary among cardiovascular biomarkers — by comparison, LDL cholesterol is far more responsive to diet, physical activity, and pharmacological intervention. For Lp(a), lifestyle modifications including dietary change, exercise, and weight loss have minimal and generally clinically insignificant effects on circulating levels.

The epidemiological footprint is substantial. Approximately 20–25% of the global population carries Lp(a) levels at or above the commonly used clinical threshold of 50 mg/dL (≥125 nmol/L), a level at which cardiovascular risk is meaningfully elevated. In aggregate, this represents an estimated 1.5 billion individuals worldwide — making Lp(a) one of the most prevalent genetic cardiovascular risk factors in existence.

Ethnicity plays a notable role in Lp(a) distribution. Data from large population cohorts, including the UK Biobank, indicate that mean Lp(a) concentrations are lowest in Chinese individuals, followed by White Europeans, South Asians, and highest in individuals of Black African descent. Postmenopausal women tend to have Lp(a) levels approximately 17% higher than men of the same age, a difference attributed to the decline in oestrogen, which appears to have a suppressive effect on Lp(a) production. Given its strong heritability, a confirmed elevated result in one individual also has direct implications for first-degree relatives, who should be offered screening.

3. Pathophysiological Mechanisms: Three Converging Risk Pathways

Research suggests that Lp(a) contributes to cardiovascular disease through at least three interconnected biological mechanisms, which together explain its association with a broader range of outcomes than most other lipoproteins.

Pro-atherogenic effects

As an LDL-like particle, Lp(a) can penetrate and accumulate within the arterial wall. Lp(a) particles are thought to be particularly atherogenic because they carry a high proportion of oxidised phospholipids (OxPL) — pro-inflammatory lipid species that drive foam cell formation, macrophage activation, and plaque development. Studies indicate that Lp(a) may transport up to 90% of all circulating OxPL, making it a central vehicle for delivering inflammatory lipid signals to the vascular wall.

Pro-thrombotic effects

The structural homology between apo(a) and plasminogen allows Lp(a) to competitively inhibit plasminogen binding to fibrin, directly impairing fibrinolysis — the breakdown of blood clots. This pro-thrombotic character means elevated Lp(a) increases the risk not only of plaque formation, but of thrombotic occlusion of already-narrowed arteries, a mechanism relevant to both myocardial infarction and ischaemic stroke.

Pro-inflammatory effects

Lp(a) promotes vascular inflammation through multiple pathways, including the activation of endothelial cells and the stimulation of inflammatory signalling. The oxidised phospholipids carried by Lp(a) are potent stimulators of inflammatory cascades including the interleukin-8 pathway, and research suggests Lp(a) may promote the expression of cell adhesion molecules that facilitate leukocyte recruitment into the arterial wall.

Calcific aortic valve disease

Beyond atherosclerosis, Lp(a) has been causally linked to calcific aortic valve disease (CAVD) — a condition in which calcium deposits accumulate on the aortic valve leaflets, progressively impairing valve function. Genome-wide association and Mendelian randomisation studies have independently confirmed this association, placing Lp(a) in the rare category of biomarkers with causal evidence for two distinct major cardiovascular conditions.

4. Risk Thresholds and Clinical Interpretation

The most widely adopted clinical risk threshold for Lp(a) is ≥50 mg/dL (≥125 nmol/L), as referenced by the European Atherosclerosis Society, the American College of Cardiology/American Heart Association, and — most recently — the 2024 National Lipid Association update, which recommends universal measurement of Lp(a) at least once in every adult.

However, the relationship between Lp(a) concentration and cardiovascular risk does not operate as a simple binary threshold. Evidence from the Copenhagen General Population Study and UK Biobank analyses suggests the risk is graded and approximately continuous — the higher the concentration, the higher the cardiovascular risk — with no inflection point at which risk definitively "switches on." HEART UK has proposed a clinically useful risk stratification framework based on nmol/L levels: minor risk (32–90 nmol/L), moderate risk (90–200 nmol/L), high risk (200–400 nmol/L), and very high risk (>400 nmol/L).

Crucially, Lp(a) risk does not operate in isolation. It stacks with other cardiovascular risk factors. An individual with borderline LDL cholesterol, mild hypertension, and Lp(a) above 200 nmol/L may carry a considerably higher overall risk profile than any of those factors would suggest individually. This is why Lp(a) measurement is not simply about flagging a high number — it is about calibrating how aggressively residual risk needs to be managed.

5. Lp(a) in the Context of Cardiovascular Biomarkers

Lp(a) should be understood within a broader cardiometabolic biomarker context rather than in isolation. Several secondary biomarkers inform interpretation and overall risk assessment:

• LDL cholesterol: High Lp(a) combined with elevated LDL is a particularly high-risk combination. Since Lp(a) particles contain approximately 30–45% cholesterol by mass, very elevated Lp(a) can measurably inflate the LDL-C value calculated by the Friedewald equation — a confound worth considering when interpreting lipid panel results.
• Apolipoprotein B (ApoB): ApoB reflects the total count of atherogenic lipoprotein particles and represents a more complete measure of atherogenic burden than LDL-C alone. In individuals with high Lp(a), ApoB provides an integrated view of cumulative particle-level risk.
• High-sensitivity C-reactive protein (hsCRP): Given the pro-inflammatory character of Lp(a) — particularly its OxPL cargo — hsCRP may be elevated in parallel and adds an independent inflammatory risk dimension to the overall picture.
• Homocysteine: Like Lp(a), elevated homocysteine is independently associated with cardiovascular risk. Both biomarkers are absent from most standard lipid panels, and both add meaningful information to a cardiovascular risk assessment conducted beyond the conventional framework.

6. Measurement of Lp(a): The Analytical Challenge

Lp(a) is one of the most analytically complex biomarkers in routine clinical chemistry, and this complexity has historically contributed to its underuse. The core challenge stems from the structural heterogeneity of apo(a) — specifically the variable number of KIV-2 repeat sequences, which differ between individuals and between alleles.

Most commercially available Lp(a) immunoassays use polyclonal antibodies that bind to the KIV-2 repeat region of apo(a). Because different individuals have different numbers of KIV-2 repeats, polyclonal assays tend to overestimate Lp(a) levels in individuals with large isoforms (many repeats) and underestimate levels in those with small isoforms (fewer repeats, who also tend to have the highest absolute Lp(a) concentrations). This systematic bias has historically distorted epidemiological associations and contributed to an underestimation of Lp(a)'s true cardiovascular risk contribution.

Two methodological approaches have significantly improved measurement accuracy:

• Isoform-insensitive immunoassays: Assays using a monoclonal antibody targeting a unique, single-copy epitope on apo(a) — such as the ELISA developed at the Northwest Lipid Metabolism and Diabetes Research Laboratories (University of Washington) — recognise each Lp(a) particle exactly once, independent of isoform size. Commercially, Denka-based assay reagents with five-point isoform-representative calibration have reduced isoform sensitivity considerably and are reported in nmol/L.
• LC-MS/MS reference method: Targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been developed as an IFCC-endorsed reference measurement procedure for Lp(a), measuring a specific apo(a) peptide and expressing results in SI units (nmol/L). It is isoform-independent and serves as the traceability anchor to which commercial assays are increasingly being calibrated.

On the question of units: Lp(a) has historically been reported in mass units (mg/dL), but this is now considered analytically unsound because immunoassays measure the protein component of Lp(a) — not its full lipid mass. The consensus across the IFCC, European Atherosclerosis Society, and most major cardiology societies is that nmol/L is the preferred unit, as it reflects particle number rather than mass and is independent of the highly variable lipid content of individual Lp(a) particles. Direct conversion between mg/dL and nmol/L using a single conversion factor is discouraged, as the ratio varies substantially depending on isoform size.

7. What Can Be Done With a High Lp(a) Result Today?

No pharmacological therapy specifically targeting Lp(a) lowering is currently approved for clinical use, and this is an important caveat for anyone receiving their first elevated result. However, the absence of a direct Lp(a)-lowering agent does not mean a high result is clinically uninformative — quite the opposite.

Current management strategies for elevated Lp(a) focus on intensive modification of co-existing cardiovascular risk factors:

• Aggressive LDL reduction: Because Lp(a) and LDL act through overlapping atherogenic pathways, reducing LDL to well below conventional targets (aiming for <70 mg/dL or <1.8 mmol/L) is a primary strategy in high-Lp(a) individuals. Statins are first-line for LDL, though they do not lower Lp(a) and may modestly increase it in some individuals.
• PCSK9 inhibitors: Monoclonal antibodies targeting PCSK9 (alirocumab, evolocumab) reduce LDL-C by approximately 60% and have been associated with modest Lp(a) reductions of approximately 25–30% in clinical trials — a secondary effect whose mechanism remains under investigation. They may be considered in individuals where high Lp(a) contributes to a residual risk burden despite statin therapy.
• Lipoprotein apheresis: The only currently approved therapy with a primary Lp(a)-lowering effect, apheresis can acutely reduce Lp(a) by approximately 35%. It is resource-intensive, requires repeated sessions, and is reserved for extreme cases — particularly individuals with very high Lp(a) and established cardiovascular disease refractory to other treatment.
• Family screening: Given the strong heritability of Lp(a), a confirmed elevated result in one individual warrants measurement in first-degree relatives. Concordance rates among siblings and parent-offspring pairs are high.

8. The Emerging Therapeutic Landscape: RNA-Based Therapies

The most significant developments in Lp(a) medicine over the past five years have come from RNA-based therapeutics — specifically antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) that suppress hepatic apo(a) production at the mRNA level.

Pelacarsen (an ASO) and olpasiran (an siRNA) have both demonstrated reductions in Lp(a) of 70–90% in Phase II trials — a magnitude of lowering orders of magnitude beyond anything achievable with existing lipid therapies. Both are currently in Phase III cardiovascular outcomes trials: Lp(a)HORIZON (pelacarsen) and OCEAN(a) (olpasiran), respectively. These trials will answer the clinically defining question: does lowering Lp(a) translate into fewer heart attacks, strokes, and cardiovascular deaths?

Results from these trials, expected in the coming years, could fundamentally reshape cardiovascular risk management — transforming Lp(a) from a risk stratification tool into an actively treatable target. For now, the field awaits outcome-level evidence before approved Lp(a)-specific therapy becomes a clinical reality.

9. Biomarker Mapping Layer

• Atherogenic lipoprotein burden → Lp(a) particle number → immunoassay (isoform-insensitive, nmol/L preferred) or LC-MS/MS reference method
• Parallel atherogenic particle burden → LDL-C, ApoB → routine clinical chemistry (enzymatic colorimetric, immunoturbidimetric)
• Systemic vascular inflammation → hsCRP → high-sensitivity immunoassay (latex-enhanced immunoturbidimetry)
• One-carbon pathway and endothelial stress → homocysteine → plasma total homocysteine by LC-MS/MS or validated immunoassay / enzymatic method

Primary biomarker: Lp(a) (particle concentration, reported in nmol/L).
Secondary contextual biomarkers: LDL-C, ApoB, hsCRP, homocysteine.
Preferred analytical method: Isoform-insensitive immunoassay calibrated to WHO/IFCC SRM-2B, or IFCC-endorsed LC-MS/MS reference measurement procedure.

10. How Biostarks Can Help

Lp(a) is joining the Biostarks Metabolic Health panel in Q3 2026 — making it possible to measure Lp(a) alongside the broader cardiometabolic and metabolic biomarker context that gives it the most interpretive value.

Because Lp(a) risk does not operate in isolation — it amplifies alongside LDL, glucose dysregulation, inflammation, and metabolic dysfunction — measuring it within a comprehensive panel, rather than as a standalone number, is the approach most likely to generate actionable insight. A measurement made once, understood in context, and tracked as other risk factors change is considerably more informative than the same number reported without metabolic surroundings.

Collection is via dried blood spot from home — no clinic visit required. Results are reported and interpreted within the broader metabolic risk picture, not as an isolated data point.

If cardiovascular disease has touched your family history, or if you have simply never had this number measured, Lp(a) is one of the highest-yield additions to a modern cardiovascular risk assessment. It is, in the clearest sense, a number worth knowing.

References

• Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association — Arteriosclerosis, Thrombosis, and Vascular Biology — Koschinsky et al. — (2022) — Source
• Lipoprotein(a) and cardiovascular disease — The Lancet — Nordestgaard & Langsted — (2024) — Source
• LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics — Annual Review of Pharmacology and Toxicology — Tasdighi et al. — (2024) — Source
• Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives — International Journal of Environmental Research and Public Health — Vinci et al. — (2023) — Source
• Lipoprotein(a) in primary cardiovascular disease prevention is actionable today — PMC / National Library of Medicine — (2025) — Source
• 2024: The year in cardiovascular disease – the year of lipoprotein(a). Research advances and new findings — Archives of Medical Science — Sosnowska, Banach et al. — (2025) — Source
• Lipoprotein(a) as a cardiovascular risk factor in controversial clinical scenarios: a narrative review — International Journal of Molecular Sciences — (2024) — Source
• Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies — Pharmacotherapy — Alhomoud et al. — (2023) — Source
• Lp(a): When and how to measure it — Clinical Chemistry and Laboratory Medicine — (2021) — Source
• The ins and outs of lipoprotein(a) assay methods — Archives of Medical Science — Atherosclerotic Diseases — Heydari, Sahebkar et al. — (2024) — Source
• Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? — Atherosclerosis — Kronenberg — (2022) — Source
• Fundamentals of lipoprotein(a) request and quantification in the clinical laboratory — PMC — (2025) — Source